|
|
| (11 intermediate revisions by 4 users not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Breast cancer]] |
| {{SI}}
| |
| '''For patient information click [[{{PAGENAME}} (patient information)|here]]'''
| |
| | |
| {{CMG}} {{AE}} {{Faizan}}; {{Ammu}}
| |
| | |
| {{SK}} Lobular Carcinoma (in situ); LCIS
| |
| ==Overview==
| |
| ==Historical Perspective==
| |
| *Lobular carcinoma in situ was first discovered by F W Foote and F W Stewart, in 1941.
| |
| | |
| ==Pathophysiology==
| |
| * Lobular carcinoma in situ (LCIS) is a condition in which there is presence of unusual cells in the [[lobule]]s of the [[breast]].<ref name="urlLobular Carcinoma in situ (LCIS) - Breast Cancer - Stanford Cancer Center">{{cite web |url=http://cancer.stanford.edu/breastcancer/lcis.html |title=Lobular Carcinoma in situ (LCIS) - Breast Cancer - Stanford Cancer Center |format= |work= |accessdate=}}</ref>
| |
| *The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
| |
| *The loss of expression of [[e-cadherin]], the [[transmembrane]] [[protein]] mediating [[epithelial]] [[cell adhesion]] has been associated with the development of lobular carcinoma in situ.
| |
| *The loss of heterozygosity on chromosome 16q has been associated with the development of lobular carcinoma in situ..
| |
| *On microscopic histopathological analysis, small cells with oval or round nuclei and small nucleoli detached from each other are [[mucin]]-containing signet-ring cells are characteristic findings of lobular carcinoma in situ
| |
| | |
| ==Causes==
| |
| * Lobular carcinoma in situ is caused by a mutation in the [[e-cadherin]] gene.
| |
| ==Differentiating Lobular carcinoma in situ from other Diseases==
| |
| *Lobular carcinoma in situ must be differentiated from other diseases that cause breast lesions, such as:
| |
| :*Ductal carcinoma insitu
| |
| :*Atypical lobular hyperplasia
| |
| ==Epidemiology and Demographics==
| |
| * The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
| |
| * In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].
| |
| ===Age===
| |
| *Lobular carcinoma in situ is more commonly observed among patients aged premenopausal women with a mean age of 45 years old
| |
| ===Race===
| |
| *There is no racial predilection for [disease name].
| |
| *[Disease name] usually affects individuals of the [race 1] race.
| |
| *[Race 2] individuals are less likely to develop [disease name].
| |
| | |
| ==Risk Factors==
| |
| *Common risk factors in the development of lobular carcinoma in situ are family history of breast cancer, hormone replacement therapy for menopause, women in early 40’s.
| |
| | |
| == Natural History, Complications and Prognosis==
| |
| *The majority of patients with [disease name] remain asymptomatic for [duration/years].
| |
| *Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
| |
| *If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
| |
| *Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
| |
| *Prognosis is generally [excellent/good/poor], and the [1/5/10year mortality/survival rate] of patients with [disease name] is approximately [#%].
| |
| == Diagnosis ==
| |
| ===Diagnostic Criteria===
| |
| *The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:
| |
| :*[criterion 1]
| |
| :*[criterion 2]
| |
| :*[criterion 3]
| |
| :*[criterion 4]
| |
| === Symptoms ===
| |
| *[Disease name] is usually asymptomatic.
| |
| *Symptoms of [disease name] may include the following:
| |
| :*[symptom 1]
| |
| :*[symptom 2]
| |
| :*[symptom 3]
| |
| :*[symptom 4]
| |
| :*[symptom 5]
| |
| :*[symptom 6]
| |
| === Physical Examination ===
| |
| *Patients with [disease name] usually appear [general appearance].
| |
| *Physical examination may be remarkable for:
| |
| :*[finding 1]
| |
| :*[finding 2]
| |
| :*[finding 3]
| |
| :*[finding 4]
| |
| :*[finding 5]
| |
| :*[finding 6]
| |
| === Laboratory Findings ===
| |
| *There are no specific laboratory findings associated with [disease name].
| |
| *A [positive/negative] [test name] is diagnostic of [disease name].
| |
| *An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
| |
| *Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
| |
| ===Imaging Findings===
| |
| *There are no [imaging study] findings associated with [disease name].
| |
| *[Imaging study 1] is the imaging modality of choice for [disease name].
| |
| *On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
| |
| *[Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].
| |
| === Other Diagnostic Studies ===
| |
| *[Disease name] may also be diagnosed using [diagnostic study name].
| |
| *Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].
| |
| == Treatment ==
| |
| === Medical Therapy ===
| |
| *There is no treatment for [disease name]; the mainstay of therapy is supportive care.
| |
| *The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
| |
| *[Medical therapy 1] acts by [mechanism of action1].
| |
| *Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].
| |
| === Surgery ===
| |
| *Surgery is the mainstay of therapy for [disease name].
| |
| *[Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
| |
| *[Surgical procedure] can only be performed for patients with [disease stage] [disease name].
| |
| === Prevention ===
| |
| *There are no primary preventive measures available for [disease name].
| |
| *Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
| |
| *Once diagnosed and successfully treated, patients with [disease name] are followedup every [duration]. Followup testing includes [test 1], [test 2], and [test 3].
| |
| ==References==
| |
| {{Reflist|2}}
| |
| [[Category:Oncology]]
| |